OtherBASIC SCIENCE INVESTIGATIONS
Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal
Heribert Hänscheid, Michael Lassmann, Markus Luster, Stephen R. Thomas, Furio Pacini, Claudia Ceccarelli, Paul W. Ladenson, Richard L. Wahl, Martin Schlumberger, Marcel Ricard, Al Driedger, Richard T. Kloos, Steven I. Sherman, Bryan R. Haugen, Vincent Carriere, Carine Corone and Christoph Reiners
Journal of Nuclear Medicine April 2006, 47 (4) 648-654;
Heribert Hänscheid
Michael Lassmann
Markus Luster
Stephen R. Thomas
Furio Pacini
Claudia Ceccarelli
Paul W. Ladenson
Richard L. Wahl
Martin Schlumberger
Marcel Ricard
Al Driedger
Richard T. Kloos
Steven I. Sherman
Bryan R. Haugen
Vincent Carriere
Carine Corone
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 47, Issue 4
April 2006
Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal
Heribert Hänscheid, Michael Lassmann, Markus Luster, Stephen R. Thomas, Furio Pacini, Claudia Ceccarelli, Paul W. Ladenson, Richard L. Wahl, Martin Schlumberger, Marcel Ricard, Al Driedger, Richard T. Kloos, Steven I. Sherman, Bryan R. Haugen, Vincent Carriere, Carine Corone, Christoph Reiners
Journal of Nuclear Medicine Apr 2006, 47 (4) 648-654;
Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal
Heribert Hänscheid, Michael Lassmann, Markus Luster, Stephen R. Thomas, Furio Pacini, Claudia Ceccarelli, Paul W. Ladenson, Richard L. Wahl, Martin Schlumberger, Marcel Ricard, Al Driedger, Richard T. Kloos, Steven I. Sherman, Bryan R. Haugen, Vincent Carriere, Carine Corone, Christoph Reiners
Journal of Nuclear Medicine Apr 2006, 47 (4) 648-654;
Jump to section
Related Articles
Cited By...
- Investigation of the Importance of Applying Various Methods of Calculation in Determining the Blood-Absorbed Dose for Patients with Differentiated Thyroid Carcinoma
- MIRD Pamphlet No. 28, Part 1: MIRDcalc--A Software Tool for Medical Internal Radiation Dosimetry
- The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
- Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH
- A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma?
- Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
- Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer
- Reply: Differentiated Thyroid Carcinoma: Is There Any Evidence for the Use of Recombinant Human TSH in Thyroid Hormone-Secreting Metastasis?
- Initial Management and Follow-up of Differentiated Thyroid Cancer in Children
- Dosimetry and thyroid cancer: the individual dosage of radioiodine
- In Vivo Formation of {gamma}-H2AX and 53BP1 DNA Repair Foci in Blood Cells After Radioiodine Therapy of Differentiated Thyroid Cancer
- Influence of Vitamin C on Salivary Absorbed Dose of 131I in Thyroid Cancer Patients: A Prospective, Randomized, Single-Blind, Controlled Trial
- Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma
- Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation
- Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients
- Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity
- 131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
- Perspective: The Case Against Radioiodine Remnant Ablation in Patients with Well-Differentiated Thyroid Carcinoma
- Role of Radioactive Iodine for Adjuvant Therapy and Treatment of Metastases
- Spatial Dose Mapping for Individualizing Radioiodine Treatment
- Lung Toxicity in Radioiodine Therapy of Thyroid Carcinoma: Development of a Dose-Rate Method and Dosimetric Implications of the 80-mCi Rule
- Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective